'Cell ther­a­py with­out cell­s': Cap­stan rais­es $175M to test in vi­vo CAR-T

Lau­ra Shawver pic­tures a world 10 years from now where cell ther­a­pies are re­placed by in vi­vo CAR-T prod­ucts. The goal is a cheap­er-to-pro­duce, less com­plex and more ac­ces­si­ble cell ther­a­py.

On Wednes­day, her San Diego-based start­up Cap­stan Ther­a­peu­tics an­nounced a $175 mil­lion Se­ries B, with back­ing from six large phar­ma com­pa­nies or their ven­ture arms, in­clud­ing John­son & John­son In­no­va­tion (al­so known as JJDC), Bris­tol My­ers Squibb, Eli Lil­ly, Leaps by Bay­er, No­var­tis Ven­ture Fund and Pfiz­er Ven­tures.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER